Vincent Wai-Sun Wong
Vincent Wai-Sun Wong is an expert in Hepatology at Prince of Wales Hospital (China) (China). As of October 2026, ScienceLeadR ranks Vincent Wai-Sun Wong in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Fatty Liver, Alcoholic. Vincent Wai-Sun Wong has authored 1,101 publications, the most recent in 2026, and is an investigator in 33 clinical trials, 6 of them ongoing. SLR score: 5,176 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1996 - 2026
Number : 1101
Citations
Main journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Long-term hepatic and extrahepatic outcomes in type 2 diabetes: final results of the prospective DM-FibroScan Study. PMID 42935238 — liver diseases, diabetes mellitus, incidence, fibrosis, liver, diabetes mellitus, type 2, fibroscan | Clin Mol Hepatol | 2026 | 0 |
| The dynamic spectrum of steatotic liver disease: the global perspective. PMID 42567912 — liver diseases, fibrosis, liver, therapeutics, alcohol drinking | Nat Rev Gastroenterol Hepatol Top journal | 2026 | 0 |
| High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity. PMID 42925568 — depression, quality of life, sleep, non-alcoholic fatty liver disease, signs and symptoms, pruritus, fatigue, work, prevalence, sleep initiation and maintenance disorders | J Clin Gastroenterol | 2026 | 0 |
| A real-world multicenter study of statins in compensated advanced chronic liver disease on hepatic decompensation and mortality outcomes. PMID 42873450 — liver diseases, mortality, liver, hydroxymethylglutaryl-coa reductase inhibitors | Hepatol Int | 2026 | 0 |
| A Markov model cost threshold analysis of potential hepatitis B virus cure regimens. PMID 42803761 — carcinoma, hepatocellular, hepatitis b virus, gastroenterology, incidence, herpesvirus 1, cercopithecine, viruses, quality-adjusted life years, hepatitis b e antigens, therapeutics, hepatitis b, hepatitis | Clin Transl Gastroenterol | 2026 | 0 |
Clinical Studies 33
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Development of a FibroScan Liver Examination Using a Single Probe NCT07400289 — liver diseases, research design, elasticity imaging techniques, liver, research, fibroscan, liver stiffness | N/A | Recruiting | 2025 |
| Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects NCT07024212 — liver diseases, injections, safety, fibrosis, pharmaceutical preparations, non-alcoholic fatty liver disease, liver, alcoholics, fatty liver, fatty liver, alcoholic | Phase 2 | Active not recruiting | 2025 |
| Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors NCT06549673 — research design, hypertension, safety, fibrosis, hepatitis, chronic, liver, esophageal and gastric varices, endoscopy, hypertension, portal, varicose veins, hepatitis | N/A | Recruiting | 2025 |
| Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter NCT06203548 — liver diseases, exercise, portion size, life style, eating, fibrosis, non-alcoholic fatty liver disease, liver, biomarkers, alcoholics, energy intake, body weight, resistance training, meals, fatty liver, fatty liver, alcoholic, dietary patterns | N/A | Recruiting | 2024 |
| Risk Factors for Hepatic Inflammation Fibrosis and Prognosis in Patients With CHB and NAFLD NCT05766449 — liver diseases, diabetes mellitus, liver cirrhosis, fibrosis, non-alcoholic fatty liver disease, neoplasms, hepatitis, chronic, liver, alcoholics, liver neoplasms, hepatitis a, risk factors, hepatitis b, fatty liver, fatty liver, alcoholic, prognosis, hepatitis b, chronic, hepatitis | N/A | Recruiting | 2022 |
LeadR Networks
Main global connection map